

38TH ANNUAL CONFERENCE Connecticut Infectious Disease Society



Thursday, October 28, 2021 Virtual Conference







Welcome to the 38th annual conference of the Connecticut Infectious Disease Society (CIDS)! In order to prioritize the health and safety of our members, guests and vendors, the Executive Board of CIDS made the difficult decision to move this annual conference to a virtual platform. We are thrilled you are with us today on Zoom and we look forward to an in-person meeting in May of 2022.

The aim of the annual conference is to promote knowledge and clinical expertise. Specifically, this year's conference is designed to address knowledge and performance gaps for infectious disease physicians, clinicians, medical students, and pharmacists.

We have created an agenda that offers a variety of exciting and timely topics and truly hope that you have an enjoyable and thought-provoking day.

- Jack Ross, MD, FIDSA, FSHEA
- David B. Banach, MD, MPH, FIDSA

THANK YOU TO OUR CONFERENCE SPONSOR





AGENDA

7:00 AM CONFERENCE OPEN - POSTER VIEWING AND VISIT WITH EXHIBITORS

8:00 AM WELCOME/INTRODUCTION

8:15 AM KEYNOTE LECTURE - ONE HEALTH; CLIMATE CHANGE & INFECTIOUS DISEASE

9:15 AM WHAT IS HOT IN HIV TREATMENT AND PREVENTION MODERATOR: LISA CHIRCH, MD SPEAKERS: HENRY ANYIMADU, MD; MICHAEL VIRATA, MD

10:15 AM BREAK WITH EXHIBITORS AND POSTER VIEWING

10:30 AM ANTIMICROBIALS - NEW DRUGS AND NEW STRATEGIES MODERATOR: MARJORIE GOLDEN, MD SPEAKERS: ASHA SHAH, MD; CASEY DEMPSEY, PHARMD

11:30 AM CT INFECTIOUS DISEASE SOCIETY UPDATE JACK W. ROSS MD, PRESIDENT

12:00 PM POSTER PRESENTATIONS, POSTER VIEWING AND VISIT WITH EXHIBITORS

1:30 PM ONCE-IN-A-CENTURY PANDEMIC-COVID-19 (PART 1) MODERATOR: DAVID BANACH, MD SPEAKERS: NATHAN GRUBAUGH, PhD; ONYEMA OGBUAGU, MBBCh


2:20 PM BREAK WITH EXHIBITORS

2:40 PM ONCE-IN-A- CENTURY PANDEMIC- COVID-19 (PART 2)

3:30 PM POST5ER AWARD WINNERS

4:00 PM CLOSING REMARKS


Zoom Instructions



The posters will also be presented in a moderated session from 12:00-13:30. Voting for the four poster awards will occur at 15:30 via four separate Zoom polls.

Connecticut Connecticut

How to use the chat room to ask questions



POSTER PRESENTATIONS

CATEGORY: YOUNG

PROVIDER PERCEPTIONS OF DECREASES IN CERVICAL CANCER SCREENING AND FOLLOW-UP DURING THE COVID-19 PANDEMIC. MARCH-OCTOBER 2020

Guinevere Oliver, Monica Brackney, Kyle Higgins, Linda Niccolai

AN OUTBREAK OF SARS-COV-2 ON A TRANSPLANT UNIT IN THE EARLY VACCINATION ERA

Carlo Foppiano Palacios, Scott Roberts, Nathan Grubaugh, Tara Alpert, Isabel Ott, Mallery Breban, Yale SARS-CoV-2 Genomic Surveillance Initiative, Richard Martinello, Cindy Smith, Matthew D. Davis, Dayna McManus, Samad Timizi, Jeffrey Topal, Marwan Azar, Maricar Malinis

CORRELATIONS OF RISK FACTORS ON SEVERITY OF DISEASE AND OUTCOME DUE TO HUMAN ADENOVIRAL RESPIRATORY INFECTIONS Luke Legakis, MD, PhD, LP, T Bandarayake

ANTIBIOTIC STEWARDSHIP: A REVIEW OF INTERNATIONAL TRAVEL MEDICINE ANTIBIOTIC USAGE AND PERCEPTION

Abigail Immanuel, MS3, Kevin Dieckhause, MD

HOSPITAL READMISSION AMONG INFANTS DIAGNOSED WITH EARLY ONSET **NEONATAL SEPSIS IN CONNECTICUT**

Rebecca Hudon, BS, Vivian Leung, MD, Susan Petit, MPH, David Banach, MD

LEGIONNAIRE'S DISEASE - A PART OF HURRICANE HENRI'S LEGACY

Collin Onwuka, MD, BS; Tinatin Murdashvili, D; Dogbey Pia, MBChB

RYAN WHITE COMPREHENSIVE CARE MODEL MARKEDLY IMPROVES RATE OF VIRAL SUPPRESSION FOR PATIENTS WITH NEW HIV DIAGNOSIS: A 10 YEAR EXPERIENCE IN NEW HAVEN. CT (2009-2018)

Alice Zhao, Christina Rizk, MSc, Xiwen Zhao, MSPH, Arit Esu, MPH, Yanhong Deng, Lydia Barakat, MD, Merceditas, MD

THIS TIME: NOT A CONTAMINANT!

Michelle Melo, MD, Hiba Zeid, MD, Pia Dogbey, MD

CATEGORY: THORTON

RISK BASED SCREENING FOR HEPATITIS C (HVC) IN PERSONS WITH HIV Ritche Hao, MD; Mercedita Villanueva, MD; Ralph Brooks

INFECTIOUS DISEASE DIVERSITY, EQUITY, AND ANTIRACISM (ID2EA): A DEDICATED CURRICULUM FOR INFECTIOUS DISEASE PROFESSIONALS

Meghan Bathgate, Jennifer Frederick, Mahalia Desruisseaux, Jamie Meyer, Michael Virata, Heidi Zapata, Sheela Shenoi, Joanna Radin, Marjorie Golden, Paul Trubin, Albert Shaw, Gerald Friedland and Lydia Aoun-Barakat

POSTER PRESENTATIONS

COVID-19 RESPONSE AND INFECTION CONTROL PROTOCOLS IN HEMODIALYSIS CENTERS IN CONNECTICUT

Colleen Lynch, David Banach, MD, MPH; Adora Harizaj, MPH, CPH; Vivian Leung, MD

ASSESSING ATTITUDES REGARDING ORGAN DONATIONS AND RECEPTION IN HIV POSITIVE INDIVIDUALS IN CONNECTICUT

Kathryn Stevens, Kevin Dieckhaus, MD

IMPROVING HIV AND HCV ROUTINE TESTING IN CT SUBSTANCE USE DISORDER TREATMENT PROGRAMS

Ralph Brooks, Maximilian Wegener, Alexei Zelenev, Lisa Nichols, Merceditas Villanueva

CATEGORY: ANDRIOLE

CANDIDEMIA SURVEILLANCE IN CT: A FIRST LOOK AT CANDIDEMIA FOLLOWING COVID-19 INFECTION M. Fitzsimmons BPH, H. Kayalioglu BPH, P. Clougher, MPH

CANDIDEMIA SURVEILLANCE IN CT: A FIRST LOOK AT CANDIDEMIA FOLLOWING COVID-19 INFECTION

M. Fitzsimmons BPH, H. Kayalioglu BPH, P. Clougher, MPH

ATTITUDES TOWARDS HCV TREATMENT WITH DIRECT ACTING ANTIVIRALS (DAAs): A QUALITATIVE ANALYSIS WITH HIV/HCV CO-INFECTED PERSONS WHO DELAY OR REFUSE TREATMENT

Sarah Brothers, Elizabeth DoDomizio, Lisa Nichols, Ralph Brooks, Merceditas Villanueva

A SUSTAINABLE SURVEILLANCE-BASED APPROACH TO CREATING A STATE-LEVEL HCV CASCASE OF CARE FOR HIV/HCV Co-INFECTED PERSONS Maximilian Wegener, MPH; Ralph Brooks, MS; Suzanne Speers, MPH; Lisa Nichols, MPH; Merceditas Villanueva, MD

CATEGORY: FRIEDLAND

UPTAKE OF HIV PRE-EXPOSURE PROHYLAXIS AT BARS IN RURAL SOUTH AFRICA

Megan Grammatico, Moll AP, Choi K, Springer S, Shenoi SV

A QUESTIONNAIRE ASSESSING ATTITUES AND READINESS FOR HIV PRE-EXPOSURE PROPHYLAXIS (PrEP) THERAPY FOR COMMUNITY MEMBERS AT-RISK FOR HIV ACQUISITION IN LIBERIA

Jessica Tuan, MDMS; Yassah Barclay-Korboi, MD; Omowumi Olarinmoye, MD; Lydia Barakat, MD; Mukhtar Adeiza, MBBS; Jamie Meye, MD; Onyema Ogbuagu, MBBCh, FACP, FIDSA



Claim CME Credits for Attendance at the 38th Annual Conference

Click Here For More Info

Upcoming HIV Clinical Trials

1) GS-US-536-5816

A Phase 1b Randomized, Blinded, Study to Evaluate the Safety & Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 & GS-2872 in Combination with Capsid Inhibitor Lenacapavir (GS-6207) in Virologically Suppressed Adults with HIV-1

INCLUSION CRITERIA

- 18 65 yo
- No resistance to current ART
- On 1st-line ART for ≥ 2 yr (change in ART ≥ 28 days allowed except for virologic failure)
- Undetectable HIV-1 VL for ≥ 18 mo. (Transient blips okay).
- CD4_{Screening} ≥ 500; CD4_{Nadir} ≥ 350
- eGFR ≥ 70 (Cockcroft-Gault)
- ALT & AST ≤ 5 × ULN. Normal ALP.
- TBili ≤ 1.5, or normal DBili

EXCLUSION CRITERIA

- History of anti-HIV-1 mAb (i.e. ibalizumab)
- Immunosuppressant/ chemotherapeutic within last 4 weeks
- HCV RNA (+)
- Chronic Hep B
- · History of:
 - Stage 3 HIV
 - Implanted defibrillator/pacemaker
 - Malignancy (within past 5 years)

Contact:

Laurie.Andrews@Yale.edu (203-376-3259), Onyema.Obuagu@yale.edu (516-281-4557), Jessica.Tuan@Yale.Edu (630-532-3325)

2) GS-US-528-9023

Phase 3 Study of Lenacapavir for HIV PrEP for Cisgender Men, Transgender Women, Transgender Men, and Gender Non-Binary Individuals who have Sex with Partners Assigned Male at Birth (PURPOSE 2)

INCLUSION CRITERIA

Incidence Phase:

- Cisgender Men, Transgender Women, Transgender Men, or Gender Non-Binary who have receptive anal sex with men
- ≥18 years (Enrollment of 16 & 17 yo post-1st indpt DMC meeting)
- HIV-1 status unknown at screening & no prior HIV-1 test 3 months prior
- Sexually active with ≥ 1 male (condomless anal sex) in past 1 year AND 1 of following:
 - a) Condomless anal sex with ≥ 2 partners in last 12 wk
 - b) No syphilis, rectal gonorrhea, or rectal chlamydia hx in last 24 wk
 - c) Self-reported stimulant use with sex in last 12 wks

Randomized Phase:

- (-) Local rapid 4th gen HIV-1 Ab/Ag
- eGFR ≥ 60
- Wt ≥ 35 kg

EXCLUSION CRITERIA

Incidence Phase:

- Prior use of long-acting systemic PrEP
 - (i.e. cabotegravir, islatravir)
- HIV vaccine recipient

Randomized Phase:

- Participation in ANY other clinical trial
- Acute Hep A, Acute or chronic Hep B/C
 - a) If HepBcAb (+), those with
 (+) HBV DNA excluded.
 - b) If HCV Ab (+), HCV RNA performed. No active HCV (OK if completed tx & had SVR)
- Osteoporosis/bone fragility fractures
- Severe hepatic impairment/ decompensated liver cirrhosis hx

Contact:

Laurie.Andrews@Yale.edu (203-376-3259), Onyema.Obuagu@yale.edu (516-281-4557), Jessica.Tuan@Yale.Edu (630-532-3325)

Thank you to our exhibitors!

Do not forget to visit them in the breakout rooms throughout the conference.

Janssen Janfectious Diseases & Vaccines

PHARMACEUTICAL COMPANIES OF Johnson Johnson

JEFF L. PEAK EXECUTIVE SALES SPECIALIST HIV INFECTIOUS DISEASES & VACCINES 860-490-3343



GILEAD Creating Possible

JACKIE HOFFMAN GILEAD SCIENCES THERAPEUTIC SPECIALIST 413-219-1514 JACKIE.HOFFMAN@GILEAD.COM





For questions, please contact: Barbara Markowitz Institutional Specialist, Gilead Sciences Mobile: 203-581-3184 Email: Barbara.Markowitz@gilead.com

Please see the Prescribing Information by visiting www.vekluryhcp.com

VKYP0174





STACEY M. MOORE, RN EXECUTIVE SPECIALTY REPRESENTATIVE CT/ NORTHEAST DISTRICT 860-305-4599 STACEY.MOORE@MERCK.COM







Carrie Mack Critical Care Specialist



Mobile 781-718-2303 Email cmack@ljpc.com

4747 Executive Drive Suite 240, San Diego, CA 92121

Web www.ljpc.com



insmed

Judy Randazzo, B.S., R.R.T. Therapeutic Specialist



EMAIL judy.randazzo@insmed.com CELL 860.463.2741

700 US Highway 202/206 Bridgewater, NJ 08807

www.insmed.com





BRIAN SURACI ASTELLAS PHARMA US 203-915-3587 BRIAN.SURACI@ASTELLAS.COM



ViiV Healthcare

MARK CROUSE TERRITORY ACCOUNT MANAGER ViiV HEALTHCARE mark.crouse@viivhealthcare.com 203-856-6556



The toughest challenges.The most advanced science.

abbvie

We fight the toughest health challenges with advanced science, putting our passion to work where the need is greatest. Our purpose as a global biopharmaceutical company is to make a remarkable impact on people's lives.

abbvie.com

People, Passion, Possibilities,*

Theratechnologies Inc.

2015 Peel St – 11th floor Montreal, Quebec, CANADA H3A 1T8 communications@theratech.com www.theratech.com

514 336-7800

Who We Are

Theratechnologies is a biopharmaceutical company established in 1993 and focused on the development and commercialization of innovative therapies addressing unmet medical needs in HIV, oncology and hepatology.

What We Bring to HIV

A passion for the HIV community which led to the first and only long-acting monoclonal antibody to block HIV replication and a novel treatment for patients with a metabolic condition that significantly impacts their quality of life.

Products

Two HIV therapies and a promising product pipeline in oncology and hepatology. Theratechnologies is committed to people in need of new therapies where there are currently none.

A Trusted Partner in HIV

The goal shared by our team is to be a trusted partner in the fight against $\ensuremath{\mathsf{HIV}}$.

Theratechnologies has a dedicated professional team throughout the U.S. comprised of: **Strategic Account Managers, Key Account Managers, Medical Science Liaisons, Community Liaisons and Reimbursement Specialists**, whose role is to ensure that we meet and exceed the needs of the HIV Community and Healthcare Providers.


Education and Awareness

To this end, we invest in people, raising awareness about HIV treatment and prevention, while providing support to everyone involved in improving the lives of patients.

Together We Can Make A Difference

Theratechnologies is driven by strong values, a deep commitment to the HIV community, and an ultimate goal to end the HIV epidemic TOGETHER.







May 12, 2022- Save The Date!

 The Event: 39th Annual Conference-Connecticut Infectious Diseases Society
 LIVE, IN PERSON!

Date & Location: Thursday, May 12, 2022-Courtyard Marriott Waterbury, 63 Grand Street, Waterbury

➤Topics to be determined

Watch for the brochure and the call for posters!